Quest Diagnostics (DGX) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Quest Diagnostics (NYSE: DGX):

• 7/28/2026 – Quest Diagnostics had its price target raised by JPMorgan Chase & Co. from $220.00 to $250.00. They now have a “neutral” rating on the stock.
• 7/28/2026 – Quest Diagnostics was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/24/2026 – Quest Diagnostics had its price target raised by UBS Group AG from $220.00 to $232.00. They now have a “neutral” rating on the stock.
• 7/24/2026 – Quest Diagnostics had its price target raised by Mizuho from $235.00 to $260.00. They now have an “outperform” rating on the stock.
• 7/24/2026 – Quest Diagnostics had its price target raised by Truist Financial Corporation from $225.00 to $250.00. They now have a “hold” rating on the stock.
• 7/24/2026 – Quest Diagnostics had its price target raised by Robert W. Baird from $236.00 to $255.00. They now have a “neutral” rating on the stock.
• 7/23/2026 – Quest Diagnostics had its price target raised by Barclays PLC from $230.00 to $250.00. They now have an “overweight” rating on the stock.
• 7/23/2026 – Quest Diagnostics had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $245.00 price target on the stock.
• 7/20/2026 – Quest Diagnostics was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/13/2026 – Quest Diagnostics had its price target raised by Robert W. Baird from $232.00 to $236.00. They now have a “neutral” rating on the stock.
• 7/12/2026 – Quest Diagnostics was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/9/2026 – Quest Diagnostics was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
• 6/28/2026 – Quest Diagnostics was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/24/2026 – Quest Diagnostics was downgraded by Weiss Ratings from “buy (b+)” to “buy (b)”.
• 6/20/2026 – Quest Diagnostics was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/9/2026 – Quest Diagnostics was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
• 5/30/2026 – Quest Diagnostics was downgraded by Wall Street Zen from “buy” to “hold”.

Quest Diagnostics Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, July 22nd. Stockholders of record on Wednesday, July 8th were given a $0.86 dividend. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend was Wednesday, July 8th. Quest Diagnostics’s payout ratio is presently 36.52%.

Insider Activity

In other news, SVP Karthik Kuppusamy sold 8,147 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the sale, the senior vice president directly owned 13,510 shares in the company, valued at approximately $2,702,000. The trade was a 37.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $194.14, for a total value of $1,941,400.00. Following the sale, the chief executive officer directly owned 132,423 shares in the company, valued at $25,708,601.22. This represents a 7.02% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.88% of the company’s stock.

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.